HusseinAbdul-HassanTawbiMD

PubMed

• Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity.
  Isabella C Glitza, Yongwoo David Seo, Christine N Spencer, Jennifer R Wortman, Elizabeth M Burton, Farah A Alayli, Christopher P Loo, Shikha Gautam, Ashish Damania, Ju...> ;Cancer Discovery. 2024 Apr 4
• The Symptom Experience of Patients with Advanced Melanoma Undergoing Immune Checkpoint Inhibitor (ICI) Therapy.
  Jackson-Carroll, N., Johnson, C., Wang, X., Whisenant, M., Tawbi, H.> ;Seminars in Oncology Nursing. 2024 Feb 1
• Real-world outcomes with immuno-oncology therapies in advanced melanoma: final results of the OPTIMIzE registry study.
  John M Kirkwood, Lisa A Kottschade, Robert R McWilliams, Nikhil I Khushalani, Sekwon Jang, Sigrun Hallmeyer, David F McDermott, Hussein Tawbi, Min Che, Cho-Han Lee, Co...> ;Immunotherapy. 2024 Jan 1
• 2 citations
  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0.
  Anna C Pavlick, Charlotte E Ariyan, Elizabeth I Buchbinder, Diwakar Davar, Geoffrey T Gibney, Omid Hamid, Tina J Hieken, Benjamin Izar, Douglas B Johnson, Rajan P Kulk...> ;Journal for Immunotherapy of Cancer. 2023 Oct 1
• 1 citations
  Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients With Solid Tumors.
  Yibirin, M., Mustafayev, K., Hosry, J., Pundhir, P., Klingen, J., Yepez Guevara, E., Granwehr, B., Kaseb, A., Naing, A., Patel, S., Shah, A., Skoulidis, F., Tawbi, H.,...> ;The American Journal of Gastroenterology. 2023 Sep 1
• 2 citations
  Gut Microbiome in Patients With Early-Stage and Late-Stage Melanoma.
  Russell G Witt, Samuel H Cass, Tiffaney Tran, Ashish Damania, Emelie E Nelson, Elizabeth Sirmans, Elizabeth M Burton, Manoj Chelvanambi, Sarah Johnson, Hussein A Tawbi...> ;JAMA Dermatology. 2023 Oct 1
• 1 citations
  Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice.
  Kourtney Augustyn, Jocelyn Joseph, Anisha B Patel, Azadeh Razmandi, Amatul Noor Ali, Hussein A Tawbi> ;Melanoma Research. 2023 Oct 1
• 3 citations
  National Cancer Institute Collaborative Workshop on Shaping the Landscape of Brain Metastases Research: challenges and recommended priorities.
  Michelle M Kim, Minesh P Mehta, DeeDee K Smart, Patricia S Steeg, Julie A Hong, Michael G Espey, Pataje G Prasanna, Laura Crandon, Christine Hodgdon, Niki Kozak, Terri...> ;The Lancet. Oncology. 2023 Aug 1
• Retraction and republication-TRICOTEL: defining symptomatic brain metastases in clinical trials.
  Reinhard Dummer, Hussein Tawbi> ;The Lancet. Oncology. 2023 Aug 1
• 29 citations
  Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.
  Reinhard Dummer, Paola Queirolo, Pauline Gerard Duhard, Youyou Hu, Dao Wang, Sergio Jobim de Azevedo, Caroline Robert, Paolo Antonio Ascierto, Vanna Chiarion-Sileni, P...> ;The Lancet. Oncology. 2023 Dec 1
• 1 citations
  Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development.
  Harriet M Kluger, Hussein Tawbi, David Feltquate, Theresa LaVallee, Naiyer A Rizvi, Elad Sharon, Jeffrey Sosman, Ryan J Sullivan> ;Journal for Immunotherapy of Cancer. 2023 Jul 1
• Novel Immunotherapeutics: Perspectives on Checkpoints, Bispecifics, and Vaccines in Development.
  Firas Y Kreidieh, Hussein A Tawbi, Aikaterini Alexaki, Hossein Borghaei, Lana E Kandalaft> ;American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2023 Jun 1
• 25 citations
  Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/...
  Ascierto, P., Lipson, E., Dummer, R., Larkin, J., Long, G., Sanborn, R., Chiarion-Sileni, V., Dréno, B., Dalle, S., Schadendorf, D., Callahan, M., Nyakas, M., Atkinson...> ;Journal of Clinical Oncology. 2023 May 20
• 10 citations
  Neoadjuvant immunotherapy for melanoma is now ready for clinical practice.
  Claus Garbe, Reinhard Dummer, Teresa Amaral, Rodabe N Amaria, Paolo A Ascierto, Elizabeth M Burton, Brigitte Dreno, Alexander M M Eggermont, Axel Hauschild, Christoph ...> ;Nature Medicine. 2023 Jun 1
• 2 citations
  Physician Views on the Provision of Information on Immune Checkpoint Inhibitor Therapy to Patients with Cancer and Pre-Existing Autoimmune Disease: A Qualitative Study.
  Maria A Lopez-Olivo, Gabrielle F Duhon, Juan I Ruiz, Mehmet Altan, Hussein Tawbi, Adi Diab, Clifton O Bingham 3rd, Cassandra Calabrese, Natalia I Heredia, Robert J Vol...> ;Cancers. 2023 May 10
• 2 citations
  The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022.
  Paolo A Ascierto, Christian Blank, Alexander M Eggermont, Claus Garbe, Jeffrey E Gershenwald, Omid Hamid, Axel Hauschild, Jason J Luke, Janice M Mehnert, Jeffrey A Sos...> ;Journal of Translational Medicine. 2023 Apr 18
• 11 citations
  Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma.
  Long, G., Stephen Hodi, F., Lipson, E., Schadendorf, D., Ascierto, P., Matamala, L., Salman, P., Castillo Gutiérrez, E., Rutkowski, P., Gogas, H., Lao, C., Janoski De ...> ;NEJM Evidence. 2023 Apr 1
• 5 citations
  Trametinib in Patients With,, or-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2.
  Kari B Wisinski, Yael Flamand, Melissa A Wilson, Jason J Luke, Hussein A Tawbi, Fangxin Hong, Edith P Mitchell, James A Zwiebel, Helen Chen, Robert J Gray, Shuli Li, L...> ;JCO Precision Oncology. 2023 Apr 1
• 1 citations
  Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trial...
  Rifaquat Rahman, Mei-Yin C Polley, Laura Alder, Priscilla K Brastianos, Carey K Anders, Hussein A Tawbi, Minesh Mehta, Patrick Y Wen, Susan Geyer, John de Groot, Gelar...> ;The Lancet. Oncology. 2023 Apr 1
• 13 citations
  Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.
  Isabella C Glitza Oliva, Sherise D Ferguson, Roland Bassett Jr, Alexandra P Foster, Ida John, Tarin D Hennegan, Michelle Rohlfs, Jessie Richard, Masood Iqbal, Tina Det...> ;Nature Medicine. 2023 Apr 1
• 3 citations
  Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: R...
  Dirk Schadendorf, Hussein Tawbi, Evan J Lipson, F Stephen Hodi, Piotr Rutkowski, Helen Gogas, Christopher D Lao, Jean-Jacques Grob, Andriy Moshyk, Jennifer Lord-Bessen...> ;European Journal of Cancer. 2023 Jul 1
• 1 citations
  Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma.
  Rodabe N Amaria, Michael Postow, Elizabeth M Burton, Michael T Tetzlaff, Merrick I Ross, Carlos Torres-Cabala, Isabella C Glitza, Fei Duan, Denái R Milton, Klaus Busam...> ;Nature. 2023 Mar 1
• 5 citations
  Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy.
  Naiyer Rizvi, Foluso O Ademuyiwa, Z Alexander Cao, Helen X Chen, Robert L Ferris, Sarah B Goldberg, Matthew D Hellmann, Ranee Mehra, Jong Chul Park, Harriet Kluger, Hu...> ;Journal for Immunotherapy of Cancer. 2023 Mar 1
• 2 citations
  Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies.
  Michael B Atkins, Paolo A Ascierto, David Feltquate, James L Gulley, Douglas B Johnson, Nikhil I Khushalani, Jeffrey Sosman, Timonthy A Yap, Harriet Kluger, Ryan J Sul...> ;Journal for Immunotherapy of Cancer. 2023 Mar 1
• 6 citations
  Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors.
  Harriet Kluger, J Carl Barrett, Justin F Gainor, Omid Hamid, Michael Hurwitz, Theresa LaVallee, Rebecca A Moss, Roberta Zappasodi, Ryan J Sullivan, Hussein Tawbi, Elad...> ;Journal for Immunotherapy of Cancer. 2023 Mar 1
• Join now to see all

Journal Articles

• Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain  
  Kim Margolin, Omid Hamid, Christopher D Lao, Anna C Pavlick, Michael A Postow, F Stephen Hodi, Nikhil I Khushalani, Marc S Ernstoff, Hussein A Tawbi, Igor Puzanov, Ahm..., The New England Journal of Medicine
• Metastatic Melanoma with balloon/histiocytoid Cytomorphology After Treatment with Immunotherapy: A Histologic Mimic and Diagnostic Pitfall  
  Michael T Tetzlaff, Priyadharsini Nagarajan, Hussein Tawbi, Victor G Prieto, Phyu P Aung, Journal of Cutaneous Pathology

Lectures

• Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204). 
  2019 ASCO Annual Meeting - 6/1/2019
• Phase I/II study of the PI3K inhibitor GSK2636771 in combination with pembrolizumab (P) in patients (pts) with PD-1 refractory metastatic melanoma (MM) and PTEN loss. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• What to Do First in Case of Melanoma Brain Metastases and Simultaneous Extracerebral Disease 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
• Current Insights Into Checkpoint Therapy for Central Nervous System Metastases 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
• Join now to see all